Renal Insufficiency Clinical Trial
Official title:
High Resolution Imaging of Retinal Vessels as a Biomarker of Cardiovascular Disease in Patients With Renal Insufficiency - (IRIR)
The objectives are to better understand, in the dialysis patient, the relationships between
microvascular morphometry and cardiovascular events, survival, arterial hypertension, the
pathology responsible for renal failure, the age of dialysis and metabolic parameters.
The investigator team also want to better understand the relationship between the diameter of
small arteries and parameters such as hypertension, the pathology that causes kidney failure,
the age of dialysis, the use of VKA or EPO, metabolic parameters (HbA1c, NFS, reticulocytes,
BNP, lipid balance, phosphocalcic balance).
The cardiovascular morbidity of a dialysis patient is 10 times higher than that of a subject
in the general population. The patient with renal insufficiency is therefore at high
cardiovascular risk. An increase in the wall-to-lumen ratio (WLR) is an early sign of
microvascular damage, predictive of the risk of a cardiovascular event. The benefits of WLR
measurement are therefore at the level of both the diagnosis and prognosis of vascular
disease. Recently, a fundus camera coupled with an adaptive optics system has been able to
measure for the first time in vivo non-invasively and reproducibly the wall thickness of the
small arteries of the retina, and therefore the WLR, among other biomarkers relating to
microvascular remodelling.
Studies in hypertension have confirmed that the rtX1 camera allows reliable and reproducible
measurements of the WLR. The main aim of our study is to evaluate the value of the WLR as a
biomarker of the risk of cardiovascular morbidity and mortality in patients with renal
insufficiency.
The objectives are to better understand, in the dialysis patient, the relationships between
microvascular morphometry and cardiovascular events, survival, arterial hypertension, the
pathology responsible for renal failure, the age of dialysis and metabolic parameters.
The investigator team also want to better understand the relationship between the diameter of
small arteries and parameters such as hypertension, the pathology that causes kidney failure,
the age of dialysis, the use of VKA or EPO, metabolic parameters (HbA1c, NFS, reticulocytes,
BNP, lipid balance, phosphocalcic balance).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
| Recruiting |
NCT04096547 -
Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
|
||
| Completed |
NCT04024332 -
Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02849964 -
Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions
|
N/A | |
| Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
| Completed |
NCT01462136 -
PK Study of ACHN-490 Injection in Renally Impaired Subjects
|
Phase 1 | |
| Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
| Completed |
NCT01172431 -
Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
|
Phase 4 | |
| Completed |
NCT01545531 -
Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance
|
N/A | |
| Completed |
NCT00770081 -
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
|
Phase 3 | |
| Completed |
NCT00765830 -
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
|
Phase 3 | |
| Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 | |
| Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
| Completed |
NCT02894385 -
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
|
Phase 1 | |
| Completed |
NCT02894905 -
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
|
Phase 1 | |
| Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
| Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
| Completed |
NCT03235375 -
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects
|
Phase 1 | |
| Withdrawn |
NCT03329612 -
Remote Ischemic Preconditioning in ACS Patients
|
N/A | |
| Recruiting |
NCT02578784 -
DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis
|
N/A |